Trial
NCT03840902
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Non-small Cell Lung Cancer
Intervention
M7824
Why stopped
Based on recommendations by an external Independent data Monitoring Committee (IDMC), Sponsor decided to discontinue this clinical study due to a low likelihood of achieving superiority in the efficacy endpoints versus standard of care.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-16